Bergua Burgués, Juan Miguel | Hematología y Hemoterapia |

Resultados: 296
Tipo Título / Nombre Autor(es) Año
Recomendaciones PETHEMA 2025 para el tratamiento de la leucemia mieloblástica aguda en pacientes ancianos (70+) y/o no no candidatos a quimioterapia intensiva (unfit). Guía asistencial Paciente Anciano Paciente Unfit (Guía PAPU-70+) Algarra L, Botella C, Vives S..., Bergua J 2025
Expression of the inhibitory checkpoints LAG-3, TIM-3, and PD-1 in NK cells and T cells in acute myeloid leukemia: preserved expression of LAG-3 is associated with patient survival Valhondo I, Pera A, Hassouneh F..., Bergua JM, Arcos MJ, Casas-Avilés I, Sánchez-García J, Serrano J, Durán E, Alonso C, Solana R, Tarazona R 2025
Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma Morschhauser F, Salles G, Sehn LH, Herrera AF, Friedberg JW..., Bergua Burgués JM 2025
Healthcare Resource Utilization and Treatment Costs for Blastic Plasmacytoid Dendritic Cell Neoplasm: A PETHEMA Study Solana-Altabella A, Navarro-Vicente I, Rodríguez-Arbolí E, Noriega V, Serrano J..., Bergua-Burgues JM 2025
Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry Alfonso-Pierola A, Martinez-Cuadrón D, Rodríguez-Veiga R, Gil C, Gil C, Gil C, Martínez-Sánchez P..., Bergua JM 2025
Prognostic relevance of variant allele frequency for treatment outcomes in patients with acute myeloid leukemia: a study by the Spanish PETHEMA registry Colmenares R, Álvarez N, Barragán E, Boluda B, Larrayoz MJ..., Bergua J 2025
Autologous or Allogeneic Hematopoietic Stem Cell Transplantation as Front-Line Treatment for Adult Secondary Acute Myeloid Leukemia Patients: The PETHEMA Registry Experience Serrano J, Martínez-Cuadrón D, Gil C, Gil C, Gil C, Bernal T, Tormo M..., Bergua J 2025
Plain language summary of the ECHELON-3 study: brentuximab vedotin combination treatment in people with diffuse large B-cell lymphoma Bartlett NL, Hahn U, Kim WS, Fleury I, Laribi K, Bergua JM 2025
Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study Westin J, Tycel JP, Amitkumar M..., Bergua Burgués JM 2025
Pivotal Results of SELECT-MDS-1 Phase 3 Study of Tamibarotene with Azacitidine in Newly Diagnosed Higher-Risk MDS DeZern AE, Thepot S, De Botton S, Patriarca A, Deeren D..., Bergua Burgues JM 2025